After Sihuan's Profit Guidance, 39x Earnings Still Look Ahead of the Good News

Sihuan's guidance supports improvement, but the stock already reflects some of it

Sihuan's first half 2026 earnings guidance points to improvement: net profit is expected to rise meaningfully. But the market is not waiting for that improvement to be fully proven. The stock trades at a P/E of 39.1x and has recently traded around HK$0.905, after a 1-month share price return of 12.05%. It is still down 27.34% year to date, so the picture is mixed: recent momentum has improved sentiment, but the longer-term chart still invites caution.

The core issue is not whether Sihuan is getting better. It is whether the current multiple already captures much of that upside before the turnaround is fully confirmed.

What the 39x multiple assumes

The guidance itself is reasonable. Sihuan says the improvement is supported by medical aesthetics, drug commercialization, associate profits and asset divestments. That fits management's stated two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses. But strategy is not the same as proven earnings quality.

A 39x earnings multiple leaves limited room for error. If one of those supporting areas disappoints, the valuation can compress before the business has had time to prove a cleaner operating model.

Why the valuation still looks early relative to price

At a HK$1.07 billion market capitalization, Sihuan is small enough for optimism to move the shares quickly. But size alone does not make the stock cheap. After the recent rally, the shares still sit well below the average analyst price target while also remaining above some intrinsic value estimates. That is a sign of divided expectations, not obvious bargains.

Investors are buying more than one good quarter

The market is not only pricing a better first half. It is also pricing the idea that Sihuan can shift from restructuring hope to more repeatable earnings power. That is possible, but the current mix of support-medical aesthetics, drug commercialization, associate profits and asset divestments-still looks easier to improve in the short term than to sustain consistently.

Management's two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses sounds stronger than a single-business recovery. In valuation terms, however, it raises the burden of proof: both businesses need to contribute reliably if the market is going to sustain a premium multiple.

Approval progress is not the same as commercial traction

The biopharma side is where expectations can creep up fastest. Sihuan has secured milestones such as drug production approval for gabapentin capsules and drug registration approval from NMPA for an innovative drug candidate. Those are useful milestones, but they do not yet prove that reimbursement, tender execution, sales effectiveness, or repeat demand are strong enough to drive sustained earnings.

If investors overweight regulatory milestones and underwrite commercial traction too early, the multiple is usually where the correction shows up first.

What would make Sihuan's valuation work from here

The valuation starts to make more sense only if Sihuan shows that the first-half improvement is a trend, not a one-quarter event. The current guidance already points to a significant increase in net profit, supported by medical aesthetics, drug commercialization, associate profits and asset divestments. That is a constructive signal, but it is not the same as a full-year proof point.

The signals investors should watch next

• Sustainability: whether the profit gain holds through the second half and into the next reporting cycle.
• Operating quality: whether growth is coming mainly from core operations rather than associate profits and asset divestments.
• Commercial proof: whether biopharma milestones such as drug production approval and drug registration approval from NMPA begin to translate into steady sales contribution.
• Strategy execution: whether the two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses starts to look like two durable drivers rather than a hopeful narrative.

If those signals strengthen together, the stock can justify being priced for growth. If they do not, Sihuan is more likely to be judged as a turnaround story that is still ahead of its valuation.